PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) appointed Peter Anastasiou as chief operating officer and named Troy Ignelzi to its board of directors, while nominating Geno J. Germano for election at its 2026 annual shareholder meeting.
Anastasiou, a former member of the company’s board, will oversee operational execution and strategic initiatives in his new role. He resigned from the board in connection with the appointment.
He brings more than 30 years of experience in biotechnology and previously served as chief executive officer of Capsida Biotherapeutics, as well as in leadership roles at Lundbeck.
Ignelzi was appointed to fill the board seat vacated by Anastasiou and will serve the remainder of the term before standing for re-election in 2026.
He currently serves as chief financial officer of Rapport Therapeutics and previously held the same role at Karuna Therapeutics, where he led financing activities including an initial public offering.
Harmony also said Geno J. Germano has been nominated for election to the board at the 2026 annual meeting, subject to shareholder approval.
Germano has more than three decades of experience in the pharmaceutical industry, including prior leadership roles at Pfizer, Johnson & Johnson, and Wyeth, as well as serving as chief executive officer of Elucida Oncology.
Antonio Gracias, a board member since 2017, will not stand for re-election at the 2026 annual meeting.
“These moves reflect our continued focus on strengthening our team,” said Jeffrey M. Dayno, president and chief executive officer of Harmony Biosciences.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.